News Brief
Summary
Virtual care company Omada Health is expanding its services to include prescribing GLP-1 and other obesity medications, alongside providing management support for these drugs, as its membership surpasses 800,000.
Key Points
- Omada Health will now prescribe GLP-1s and other obesity drugs and assist patients in managing them.
- The expansion is part of its weight management program, responding to a growing market potentially worth $100 billion.
- The service includes support from licensed providers, nutrition guidance, health coaches, and exercise specialists.
- This aims to help patients stay on treatments longer, manage side effects, and adjust dosages as needed.
- The offering is an add-on for employer and health plan partners to control costs and improve treatment outcomes.
- Omada also reported its quarterly earnings, highlighting its role in the virtual care ecosystem for chronic conditions.
新闻简报
总结
虚拟医疗公司 Omada Health 正在扩展其服务，开始提供 GLP-1 和其他肥胖症药物的处方服务，并帮助患者管理这些药物，其会员人数已超过 80 万。
关键点
- Omada Health 将开始开具 GLP-1 类药物和其他肥胖症药物处方，并协助患者进行用药管理。
- 此次服务扩展是其体重管理计划的一部分，旨在应对一个潜在价值高达 1000 亿美元的增长市场。
- 服务内容包括由持照医疗服务提供者提供支持、营养指导、健康教练和运动专家辅导。
- 目标是帮助患者坚持更长时间的治疗、管理副作用并根据需要调整剂量。
- 该服务是面向雇主和健康计划合作伙伴的附加项目，旨在控制成本并改善治疗结果。
- Omada 还公布了季度收益，强调了其在慢性病虚拟护理生态系统中的作用。
Original Article Link: https://www.cnbc.com/2025/11/06/omada-health-to-start-prescribing-glp-1s-other-obesity-medications.html